STAFF BOARD
Article
CHAIRMAN
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 22 - Issue 2, April-June 2020
SHORT REPORTS
BEZLOTOXUMAB FOR PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN CANCER PATIENTS: REPORT OF CLINICAL CASE
ROGADO VEGAS BERTA, SÁNCHEZ GUNDÍN JULIA, GÓMEZ GÓMEZ DAVID, VALERO DOMÍNGUEZ MARTA


Bezlotoxumab (human antitoxin monoclonal antibody that binds with high affinity to Clostridium difficile toxin B neutralizing its activity) is an innovative therapy in the prevention of recurrent Clostridium difficile infection (CDI), a growing problem both at hospital level and in the community and with no published data from real-life experience. In the case of oncological patients with chemotherapy (this case), recurrent CDI is especially relevant, as it implies delays in antineoplastic administration affecting the course of the disease.

BEZLOTOXUMAB — CHEMOTHERAPY — CLOSTRIDIUM DIFFICILE — PREVENTION — RECURRENCES



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25